F-Prime Capital

Toku is an account receivable platform designed for companies that collect recurring revenue in Latin America, enabling them to enhance their collection processes at the lowest possible cost while providing an exceptional experience to their customers. It is specifically tailored for industries like insurance companies, credit institutions, telecommunications firms, real estate agencies, education, utility services, and membership-based organizations.

Bluebird Kids Health is launching a proprietary technology platform to proactively manage and coordinate treatment, with AI enhancing and simplifying the experience for its clinical team.

Ethena provides derivative infrastructure in order to transform Ethereum into the first crypto-native yield bearing stablecoin.

Teleo specializes in converting existing fleet into supervised autonomous robots. It enables operators to control machines from miles away, instantly switching between machines and across job sites. Teleo increases the operator's productivity, enhances crew safety, and features advanced Jobsite insights.

Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system.

Xaira Therapeutics is an integrated biotechnology company focused on revolutionizing drug discovery and development through the application of artificial intelligence. Headquartered in the San Francisco Bay Area, Xaira combines expertise in machine learning, extensive biological and clinical data generation, and robust therapeutic product development. By harnessing advanced AI techniques, the company aims to enhance the understanding of biological processes and improve the effectiveness of therapies. Xaira's approach encompasses all stages of drug discovery, striving to transform how diseases are treated and enabling clients to deliver innovative therapeutic solutions.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.

Teleo specializes in converting existing fleet into supervised autonomous robots. It enables operators to control machines from miles away, instantly switching between machines and across job sites. Teleo increases the operator's productivity, enhances crew safety, and features advanced Jobsite insights.

OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancer patients around the world. It is founded by Bing Yuan, Eric Slosberg, and Andy Fu.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

Warmly, Inc. is a software company that provides an autonomous revenue orchestration platform tailored for small and midsize business (SMB) revenue teams. Established in 2019 and based in Redwood City, California, Warmly's platform utilizes metadata from sales enablement tools, B2B intent data, and enrichment tools to identify and connect with website visitors primed for conversion. By aggregating and integrating insights from various sources, the platform enables users to efficiently track leads, prevent customer churn, cross-sell into new departments, and facilitate warm introductions. This comprehensive approach helps sales teams engage in meaningful conversations with qualified prospects, ultimately enhancing their lead generation and sales effectiveness.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.

BTP Automation specializes in optimizing corporate travel through its advanced hotel sourcing management platform. The company collects and analyzes hotel data from various sources to identify automated cost-saving opportunities. Its technology provides travel buyers with real-time insights into key performance indicators, enhancing the management of hotel programs. By streamlining processes and offering strategic hotel management solutions, BTP Automation enables clients to maximize the value of their travel programs while gaining deeper insights into hotel attachment rates. This focus on business intelligence and analytics helps organizations improve their overall travel efficiency and cost-effectiveness.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational small interfering RNA (siRNA) medicine aimed at treating preterm preeclampsia. The company is committed to ensuring that all women and their babies have access to safe and effective therapies for life-threatening complications during pregnancy. Comanche Biopharma's mission emphasizes the importance of evidence-based and affordable solutions, enabling women to receive cost-effective treatments that address the root causes of preeclampsia.

Adcentrx Therapeutics is a biotechnology company dedicated to advancing the development of protein conjugate therapeutics aimed at treating cancer and other serious diseases. The company focuses on creating targeted therapies that leverage the precise targeting capabilities of biologics combined with the therapeutic effectiveness of small molecule payloads. Through its innovative approach, Adcentrx seeks to enhance patient treatment options, offering next-generation therapies that aim to improve outcomes for individuals facing life-threatening conditions.

SpectrumAi is a digital health company innovating Autism care to increase access to high-quality ABA therapy for kids on the spectrum around the world. With support from industry veterans in technology and healthcare, SpectrumAi is working with global clinical leaders in ABA therapy, parents, and payers to modernize.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Elucidata Corporation, founded in 2015 and headquartered in New Delhi, India, specializes in accelerating drug discovery through its proprietary SaaS platform, Polly. This platform transforms drug discovery by delivering machine learning-ready biomedical molecular data, supported by a vast repository of over 230,000 multi-omic datasets, with more than 50,000 datasets added monthly. Polly curates this data semi-automatically, enabling data-driven drug discovery teams to integrate proprietary and public biomedical data for machine learning applications. By adhering to the FAIR guidelines, Polly's Data Lakes provide exclusive access to curated multi-omics data, facilitating faster identification of therapeutic assets with a higher likelihood of clinical success. The platform has proven instrumental in detecting validated drug targets across various fields, including immunology, oncology, and metabolomic disorders. Elucidata collaborates with leading organizations such as Pfizer, Agios Pharmaceuticals, and Genentech, as well as over 35 research partners from prominent biopharma companies and research institutions, enhancing decision-making processes in drug research and development.

Seis is an online banking platform focused on serving Spanish speakers in the United States. The platform provides a range of banking services, including savings accounts, prepaid cards for both online and offline purchases, bill payment solutions, and money transfer options. Seis also offers customizable cards to meet individual preferences and features video and chat-based customer support to enhance the banking experience. Through its comprehensive suite of services, Seis aims to deliver accessible and user-friendly banking solutions to its customers.

Latchel, Inc. is a technology company that specializes in providing an online platform for maintenance coordination tailored for property managers and landlords. Founded in 2016 and located in Bellevue, Washington, Latchel's software allows property management companies to efficiently track maintenance requests, select vendors, and enhance tenant satisfaction. The platform facilitates communication between tenants and property managers through a mobile application, enabling residents to schedule maintenance and address tasks promptly. By streamlining operations, Latchel aims to improve net margins for property managers and elevate the overall quality of maintenance services offered to residents.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

CHARM Therapeutics is focused on developing innovative medicines using advanced 3D deep learning and drug discovery technologies. The company's platform aims to address undruggable disease targets, providing healthcare professionals with effective treatment options for challenging medical conditions. By leveraging cutting-edge technology, CHARM Therapeutics seeks to create transformative therapies that have the potential to significantly improve patient outcomes.

Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

Teleo specializes in converting existing fleet into supervised autonomous robots. It enables operators to control machines from miles away, instantly switching between machines and across job sites. Teleo increases the operator's productivity, enhances crew safety, and features advanced Jobsite insights.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. It specializes in creating rapid diagnostic tests, including those for detecting infectious diseases such as coronavirus. The company offers diagnostic kits that enable medical professionals to test patients efficiently, enhancing the ability to identify infections quickly. Additionally, Proof Diagnostics is working on a smart, portable system aimed at improving the detection of various infectious diseases, thereby contributing to advancements in public health and disease management.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree specializes in connecting pharmaceutical and healthcare brands with healthcare professionals (HCPs). The platform enables targeted advertising and provides data analytics to help clients effectively reach and engage with HCPs in a compliant manner. Utilizing artificial intelligence and data segmentation, Doceree identifies specific HCPs across various digital platforms, including physician networking sites, medical journals, and telemedicine platforms. This approach allows healthcare industry professionals to deliver precise and transparent messaging at scale, catering to the needs of media agencies, pharmaceutical brands, medical device companies, consumer healthcare brands, and hospitals.

Eleos Health develops innovative health technology solutions aimed at enhancing decision-making for clinicians in the behavioral health sector. The company's AI-powered Speech-to-Insights system operates during mental health sessions to analyze voice data in real time. By gathering insights on patients through this voice technology, Eleos Health enables clinicians to deliver personalized, efficient, and cost-effective care. The automated nature of the system helps streamline the clinical process, ultimately supporting mental health professionals in providing the necessary care and support for their patients.

AmplifyMD is a telemedicine platform that connects over 3,300 medical institutions, particularly in rural and underserved areas, with a network of specialists. By offering a customized telehealthcare system, AmplifyMD enables hospitals to access on-demand specialists remotely, facilitating specialty coverage through virtual care. The platform not only streamlines clinical workflows but also automates billing processes, integrating smoothly with existing electronic health records (EHRs). This service helps hospitals minimize unnecessary patient transfers and reduces the need for costly locum tenens, ultimately improving patient care and operational efficiency.

Aerium Therapeutics focuses on the discovery and development of novel monoclonal antibodies and antiviral treatments aimed at combating SARS-CoV-2 variants. The company is dedicated to creating a pipeline of biologics and small molecule antivirals, specifically designed to address pandemic and epidemic threats. Its fully integrated discovery platform utilizes a wide network of international collaborations and established research infrastructures. This approach enables the development of targeted antigens for both the treatment and prevention of COVID-19, as well as emerging variants of the virus.

Mathison is a technology company that specializes in diversity hiring and retention. Its platform provides a comprehensive solution for organizations looking to enhance their diversity, equity, and inclusion (DEI) efforts. This includes tools for top-of-funnel diversity sourcing, bias reduction in hiring processes, and strategies to engage the entire team in diversity initiatives. Mathison's services cater to a variety of clients, including well-known brands, and focus on sourcing underrepresented candidates while ensuring job seekers' identities are protected. The platform also functions as a recruitment marketplace, centralizing talent networks to facilitate personalized job opportunities and effective DEI strategy management.

Rialtic operates an open marketplace enterprise platform that assists payers in achieving accurate healthcare payments. The platform features a reference source repository and curated content, along with payment accuracy technology designed to help users minimize costs associated with payment accuracy. By streamlining the process, Rialtic enables payers to adapt more easily to changes in the healthcare landscape and fosters innovation in payment solutions.

Canary Technologies LLC, based in San Francisco, California, specializes in developing innovative software solutions for the hospitality industry, focusing on enhancing operational efficiency and improving guest experiences. The company's platform modernizes outdated hotel management processes by offering features such as contactless check-in, digital authorizations, electronic signatures, and a customizable amenity store. These tools are designed to streamline workflows, reduce costs, increase revenue, and enhance compliance, making them invaluable to hoteliers. Trusted by numerous prestigious hotel brands worldwide, Canary Technologies aims to drive greater productivity and minimize fraud within the sector.

Expressable is an online speech therapy practice that focuses on enhancing communication for individuals with speech and language disorders, particularly children. By employing a parent-focused care model, Expressable integrates speech therapy techniques into the daily lives of users, thereby improving outcomes and experiences. The platform offers a range of services, including therapy for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. It facilitates consistent practice through weekly activities, enabling users to develop their communication skills effectively.

Parrot Software offers the most innovative and best software, hardware, and process consulting solutions for point of sale and satellite optimization satisfaction of our restaurant and/or fast-food customers. The software handles all of the expected tasks, including customer payments, ordering, seating, and data visualization.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Notabene, Inc. is a New York-based company that offers a software as a service (SaaS) platform focused on crypto compliance for the financial industry. Established in 2020, Notabene provides businesses with tools to meet emerging global regulations for cryptocurrency transactions, particularly the Travel Rule. Its platform features a unified API and a comprehensive dashboard designed to assist compliance officers in managing risks associated with both Travel Rule and non-custodial transactions. By simplifying compliance processes, Notabene enables financial companies to engage with a broader range of crypto businesses, enhancing transaction confidence and supporting growth in their operations.

Hone is a live learning platform for management training that cultivates soft skills with hard data. Hone blends the best of expert-led small group training, peer learning, continuous reinforcement, and a technology platform to develop better leaders, managers, and teammates for today’s workplace. The company's platform helps to expand, connect, and let leaders analyze the impact of the training on the organization to provide improvement for team development. Hone was established in 2018 by Tom Griffiths and Savina Perez in Encinitas, California.

Patina is a healthcare provider focused on enhancing the aging experience for older adults and their families. The company has developed a care model that prioritizes the unique needs and values of this demographic. By offering personalized and on-demand services, Patina aims to create a healthcare experience that is both human-centered and supportive. This approach allows families to actively participate in the care of their loved ones, ensuring that older adults receive the attention and respect they deserve as they navigate the challenges of aging. Patina's mission is to empower individuals to live their best lives and maintain their dignity as they age.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Burro is a developer of an autonomous farming platform designed to enhance productivity in agricultural settings. The company creates robotic tools that autonomously follow workers and transport cargo, alleviating them of physically demanding tasks that do not add significant value. By automating these labor-intensive activities, Burro enables farmworkers to concentrate on more critical functions, ultimately improving operational efficiency. Additionally, the tools capture essential data to facilitate further automation of farm work, aligning with the long-term goal of automating tedious outdoor tasks. Through its innovative approach, Burro aims to support farmers in optimizing their operations and fostering growth.

Burro is a mobile application for Android and iOS devices that offers delivery and on-demand moving services to its users. The application enables its users to request pickups by filling up their personal information and items required. The platform offers its services to individuals and businesses. Its delivery portfolio consists of household goods, carpets, wood, and retail store items. Burro was launched in 2014 by Jason Ervin and Ethan Hurtado and is based in Texas.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

Logixboard, Inc. is a Seattle-based company established in 2016 that specializes in developing a cloud platform specifically for freight forwarders. This platform enhances transparency and communication between logistics service providers and their customers. As a white-labeled customer experience software, Logixboard allows these providers to increase sales and improve customer retention by integrating seamlessly with their existing internal systems. The implementation of Logixboard's solution can be completed in less than three weeks with minimal effort from the logistics teams. Additionally, the platform offers real-time tracking and big data analytics, equipping the supply chain and logistics sector with the necessary tools to stay competitive amidst the ongoing digitization of the industry.

Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.

AppliedVR, Inc. is a Los Angeles-based company founded in 2013 that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management. The company’s flagship product, EaseVRx, is a VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. By integrating principles of cognitive behavioral therapy and mindfulness, EaseVRx provides a comprehensive approach to managing chronic pain, addressing biological, psychological, and social factors. This platform allows patients to self-administer treatment at home, offering flexibility and promoting better quality of life. AppliedVR has established strategic partnerships with prominent healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles, furthering its mission to empower patients in their pain management journey.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services, including commercial negotiations, renewal management, and contract logistics. By leveraging a vast dataset from numerous transactions, Vendr empowers finance and procurement teams to make informed decisions, find suitable software solutions, and negotiate fair prices. The platform facilitates the entire purchasing process, from discovering new tools to managing upcoming renewals, thereby helping clients to minimize software expenses. Recently, Vendr raised significant funding and expanded its capabilities through the acquisition of Blissfully, a SaaS management platform.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach using Engenious vectors. These vectors are engineered to facilitate the delivery of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the need for stem cell collection or harmful pre-treatment procedures like chemotherapy. This unique capability allows Ensoma to administer therapies through a single injection, making it possible to deliver effective treatments in outpatient settings and areas with limited access to advanced healthcare systems. By streamlining the process of gene therapy, Ensoma aims to enhance the accessibility and curative potential of genomic medicine for patients with various diseases.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

ConnexPay transforms payment acceptance and issuance for Travel and E-commerce providers which act as intermediaries. By offering clients a revolutionary way to minimize risks and reduce credit and debit card acceptance costs through linked real-time payments issued to suppliers, ConnexPay’s clients avoid the need for large lines of credit or personal guarantees. ConnexPay provides a comprehensive, integrated payments solution which incorporates powerful anti-fraud detection along with PCI-certified payment acceptance and payment issuance — driven by ConnexPay’s patent pending intelligent routing and single-use virtual cards — to handle every step of the process. Through a single provider under a simple contract, Travel and E-commerce providers can accept payments from clients and issue payments to suppliers with single-use virtual cards from multiple major card brands. ConnexPay’s advanced solution does not require clients to obtain large lines of credit, provide large reserves, or prepay for most services. Their difference makes all the difference.

Argyle develops a payroll connectivity platform that enhances financial services by providing real-time income and employment data. The platform automates various processes, including verifications, background checks, account funding, direct deposit switching, premium calculations, and wage advancements. By streamlining these functions, Argyle enables businesses and financial institutions to improve their onboarding and account management processes, thereby facilitating modern financial solutions.

Ashby is a developer of recruitment software specifically designed for high-growth companies. The company offers an enterprise-grade platform that streamlines the hiring process, making it more effective for company leaders, recruiters, and hiring managers. By providing a user-friendly solution, Ashby enables organizations of various sizes to enhance their recruitment strategies and meet their growth objectives more efficiently.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

Owkin is an artificial intelligence company founded in 2016 with offices in New York and Paris, focused on improving patient outcomes through innovative technology. The company utilizes AI to enhance drug discovery and development, particularly in oncology, by identifying new drug candidates, de-risking clinical trials, and creating diagnostic tools. Owkin's offerings include Okwin Lab, which connects data by therapeutic area; Okwin Loop, which features validated models; and a comprehensive software stack for full-service solutions. The company employs federated learning, enabling collaboration among medical and biopharma partners to extract insights from disparate datasets while safeguarding patient privacy. Owkin has developed a catalog of 30 validated models, with an additional 40 in development, and has raised over $255 million in funding, achieving unicorn status in November 2021. Co-founded by Thomas Clozel and Gilles Wainrib, Owkin aims to transform the landscape of healthcare by delivering tailored treatments for individual patients.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

AvantStay, Inc. is a hospitality company founded in 2016 and based in Los Angeles, California, specializing in vacation rental homes. The company operates a next-generation platform that redefines travel and investment experiences by offering a highly curated selection of short-term rental properties tailored to guests' needs. With a portfolio exceeding 450 premier properties across more than 60 cities, AvantStay utilizes proprietary technology to facilitate seamless bookings and efficient property management. The company has established partnerships with various online travel agencies, enabling direct bookings and enhancing accessibility for travelers. AvantStay aims to provide an elevated and authentic experience for its customers while maintaining an asset under management exceeding $800 million.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Owkin is an artificial intelligence company founded in 2016 with offices in New York and Paris, focused on improving patient outcomes through innovative technology. The company utilizes AI to enhance drug discovery and development, particularly in oncology, by identifying new drug candidates, de-risking clinical trials, and creating diagnostic tools. Owkin's offerings include Okwin Lab, which connects data by therapeutic area; Okwin Loop, which features validated models; and a comprehensive software stack for full-service solutions. The company employs federated learning, enabling collaboration among medical and biopharma partners to extract insights from disparate datasets while safeguarding patient privacy. Owkin has developed a catalog of 30 validated models, with an additional 40 in development, and has raised over $255 million in funding, achieving unicorn status in November 2021. Co-founded by Thomas Clozel and Gilles Wainrib, Owkin aims to transform the landscape of healthcare by delivering tailored treatments for individual patients.

Renshu Medical is an otolaryngology specialist chain covering areas such as suppurative otitis media, allergic rhinitis, chronic sinusitis and thyroid cancer. It provides users with Danish ear hearing detection, nasal endoscopy video examination and nasopharyngoscopy, specialists test report interpretation and other services; and can use WeChat appointment appointment time, appointment hospital experts.

Castle enables online businesses of all sizes to detect and prevent user account fraud, a technology previously only available to banks and large financial institutions. Whether you’re building a bitcoin service, e-commerce store, mobile app, or any other customer-facing application, Castle's API's lets you add account hijack protection. Castle tracks fraudsters based on device fingerprint, keystrokes, site browsing history, and hundreds of other signals. Whenever something suspicious occurs, both the administrator and account owner are alerted and can immediately take appropriate action.

Castle manages rental homes for landlords using automation and on-demand labor. It finds tenants, collect rent, and coordinate maintenance, allowing owners to kick back, relax, and never worry about their rental properties again. Owners either have to deal with this whole mess themselves, or spend 10% of their rental income on a traditional property management company that requires constant supervision and is often incentivized to act against the owner’s best interest. There are 43 million rental units in the United States, and most of them are currently managed with some combination of faxes, mail, and unreturned voicemails on the landlord’s personal phone. Castle moves all of property management into a seamless online experience, providing owners with transparency, speed, and incredible customer service—plus huge cost savings over traditional management. Renters get great service and instant updates about important issues.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

B-One is a manufacturer of artificial joints.

Notable is an AI-driven platform designed to enhance healthcare operations and improve physician-patient interactions. Deployed at over 10,000 care sites, it automates more than a million repetitive workflows daily, including processes related to registration, scheduling, authorizations, and chart reviews. The platform features a voice-powered application that organizes physician-patient conversations and dictations while securely recommending appropriate billing codes. By streamlining these tasks, Notable reduces manual workload for caregivers and fosters personalized care for patients, ultimately contributing to better financial health for healthcare providers.

AvantStay, Inc. is a hospitality company founded in 2016 and based in Los Angeles, California, specializing in vacation rental homes. The company operates a next-generation platform that redefines travel and investment experiences by offering a highly curated selection of short-term rental properties tailored to guests' needs. With a portfolio exceeding 450 premier properties across more than 60 cities, AvantStay utilizes proprietary technology to facilitate seamless bookings and efficient property management. The company has established partnerships with various online travel agencies, enabling direct bookings and enhancing accessibility for travelers. AvantStay aims to provide an elevated and authentic experience for its customers while maintaining an asset under management exceeding $800 million.

Metcela Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for cardiac diseases. Founded in 2016 and based in Kawasaki, Japan, Metcela specializes in fibroblast-based treatments, particularly its lead asset, MTC001. This therapy utilizes VCAM-1-positive Cardiac Fibroblasts, which are derived from the patient's own heart cells. Rather than replacing damaged cells, the therapy enhances the body's natural healing processes to repair heart tissue and restore a favorable microenvironment. Through its research and development efforts, Metcela aims to offer patients an effective and affordable alternative for treating heart failure.

Engine by MoneyLion is a financial technology company that specializes in embedded finance and marketplace platforms for financial services. The company offers a comprehensive suite of tools, including a search, comparison, and recommendation engine for various financial products, as well as tools for offer management and optimization. These services empower businesses to integrate financial products into their operations, enabling them to deliver personalized financial offers to their clients. Additionally, Engine by MoneyLion provides a diverse range of financial services, including loans, credit, insurance, and savings account solutions.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.